On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

ACSL4

acyl-CoA synthetase long chain family member 4

ACSL4 encodes an enzyme that activates long-chain fatty acids for incorporation into cellular lipids, with variants linked to X-linked intellectual disability. The ACSL4 gene produces an enzyme responsible for attaching coenzyme A to long-chain fatty acids, a critical step for building and remodelling cell membranes.

Chromosome Xq23 Various HGNC:3571 Tier C
ACSL4 Xq23 p arm q arm X

ACSL4 is located on the long (q) arm of chromosome X, at band Xq23. Arm ratio per GRCh38 - banding schematic.

Explore chromosome X in the library →

Available at Jeen Health

Clinical tests that include this

Overview

ACSL4 encodes acyl-CoA synthetase long-chain family member 4, an enzyme that catalyses the activation of long-chain fatty acids by linking them to coenzyme A. This activation step is essential for incorporating fatty acids into phospholipids, the structural components of cell membranes. The gene resides on the X chromosome, and pathogenic changes predominantly affect males due to hemizygosity. Loss of ACSL4 function impairs membrane composition and cellular signalling, with particularly pronounced effects in the developing nervous system. The condition is recognised in UK clinical genomics pathways for intellectual disability assessment.

What the gene does

ACSL4 catalyses the conversion of long-chain fatty acids-particularly arachidonic acid and other polyunsaturated fatty acids-into their acyl-CoA derivatives. These activated fatty acids serve as substrates for incorporation into phospholipids, which form the bilayer structure of all cellular membranes. ACSL4 plays a selective role in arachidonic acid metabolism, influencing the composition of membrane lipids in neurons and other cells. By controlling which fatty acids enter lipid biosynthetic pathways, the enzyme affects membrane fluidity, receptor function, and intracellular signalling. The protein localises to the endoplasmic reticulum and mitochondria-associated membranes, positioning it at key sites for lipid synthesis and remodelling. Disruption of ACSL4 activity alters the balance of polyunsaturated fatty acids in brain tissue, which is thought to underlie the neurodevelopmental features observed in affected individuals.

Video: Genetics 101

Chromosome location

ACSL4 is located on the long arm of the X chromosome at band Xq23. The gene spans multiple exons encoding a 711-amino-acid protein. Its position on the X chromosome means that males inherit only one copy, making them more vulnerable to loss-of-function variants. Females typically carry two X chromosomes and may exhibit variable expression depending on X-inactivation patterns.

Protein structure

Domain architecture has not been experimentally characterised in detail for this protein.

Key variants

Pathogenic variants in ACSL4 include loss-of-function changes such as nonsense mutations, frameshifts, and deletions that abolish enzyme activity. Missense variants affecting conserved residues within the catalytic core can also impair substrate binding or enzymatic function. The majority of reported pathogenic variants are found in males presenting with intellectual disability, though carrier females may occasionally show mild features due to skewed X-inactivation.

196
Total variants catalogued in ClinVar
View all on ClinVar →
14 Pathogenic / Likely pathogenic 128 Uncertain significance 45 Benign / Likely benign 9 Conflicting or other

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
GRCh37/hg19 Xq23(chrX:108919564-108929311)
copy number loss
- Pathogenic ★☆☆☆ Ischemic stroke
c.1235dup
Duplication
p.Met413fs Pathogenic ★☆☆☆ Intellectual disability, X-linked 63
c.727C>T
single nucleotide variant
p.Arg243Ter Pathogenic ★☆☆☆ not provided
c.802del
Deletion
p.Leu268fs Pathogenic ★☆☆☆ Intellectual disability, X-linked 63
c.845_846del
Deletion
p.His282fs Pathogenic ★☆☆☆ not provided
c.1003-2A>G
single nucleotide variant
- Pathogenic - Intellectual disability, X-linked 63
c.1585C>A
single nucleotide variant
p.Arg529Ser Pathogenic - Intellectual disability, X-linked 63
c.1001C>T
single nucleotide variant
p.Pro334Leu Likely pathogenic ★☆☆☆ Intellectual disability, X-linked 63
c.1072_1073del
Microsatellite
p.Leu358fs Likely pathogenic ★☆☆☆ Intellectual disability, X-linked 63
c.1315+1G>A
single nucleotide variant
- Likely pathogenic ★☆☆☆ Intellectual disability, X-linked 63

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Pathogenic variants in ACSL4 cause X-linked intellectual disability, characterised by developmental delay, learning difficulties, and variable neurological features. Affected males may present with delayed speech, motor coordination problems, and behavioural challenges. The severity of cognitive impairment ranges from mild to moderate. Some individuals exhibit additional features such as epilepsy or minor physical anomalies, though the core phenotype centres on neurodevelopmental delay.

No disease links recorded for this gene in our reference set.

UK clinical status

ACSL4 is included on the NHS Genomic Medicine Service Developmental Disorders Genotype-to-Phenotype (DDG2P) panel with green classification, indicating strong evidence for disease association. The gene also appears on the Intellectual Disability panel (R29, green rating), supporting its use in diagnostic testing for individuals with unexplained developmental delay and intellectual disability. These panel memberships guide UK laboratories in variant interpretation and reporting.

Frequently asked questions

Why does ACSL4 primarily affect males?

ACSL4 is located on the X chromosome, and males have only one copy. A single pathogenic variant therefore eliminates enzyme function, whereas females with two X chromosomes often retain some activity from the unaffected copy.

What is the role of fatty acid activation in the brain?

Activated fatty acids are incorporated into the phospholipids that form neuronal membranes. These lipids influence membrane fluidity, receptor signalling, and synaptic plasticity, all critical for normal brain development and cognitive function.

Can carrier females have symptoms?

Most female carriers are unaffected, but in rare cases skewed X-inactivation can lead to mild developmental or learning difficulties. Genetic counselling can clarify individual risks and inheritance patterns.

Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 21 June 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .